Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

United Therapeutics Corp

NASDAQ: UTHR · Life Sciences · 48 alerts · CIK 1082554

Share price
$587.88Close, Nov 16
Market cap
$25B
Shares outstanding
42.59MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All United Therapeutics Corp filings on SEC EDGAR ↗

4:34 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.64M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $587.00 to $597.33 a share (average $593.52) in 11 transactions, worth $5.64M in total on Nov 12, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$5.64M
Shares
9,500
Average price
$593.52
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Nov 12, 2026
4:39 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.64M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $584.20 to $598.63 a share (average $593.99) in 14 transactions, worth $5.64M in total on Nov 11, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$5.64M
Shares
9,500
Average price
$593.99
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Nov 11, 2026
4:38 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.57M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $577.52 to $592.93 a share (average $586.32) in 14 transactions, worth $5.57M in total on Nov 10, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.57M
Shares
9,500
Average price
$586.32
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Nov 10, 2026
4:36 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $944K of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 1,614 shares of United Therapeutics Corp at $583.80 to $585.63 a share (average $584.59) in 3 transactions, worth $944K in total on Nov 9, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$944K
Shares
1,614
Average price
$584.59
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Nov 9, 2026
4:35 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.52M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 7,886 shares of United Therapeutics Corp at $556.52 to $582.79 a share (average $572.69) in 24 transactions, worth $4.52M in total on Nov 9, 2026. Shares held after the trade: 326,057 (-0.5%).

Value
$4.52M
Shares
7,886
Average price
$572.69
Role
Chairperson & CEO
Holding change
-0.5%
Trade date
Nov 9, 2026
4:34 PM ET Form 4
Insider Selling

United Therapeutics Director Christopher Patusky Sells $702K of Stock

Christopher Patusky, Director, sold 1,210 shares of United Therapeutics Corp at $580.00 a share, worth $702K in total on Nov 9, 2026. Shares held after the trade: 2,140 (-36.1%).

Value
$702K
Shares
1,210
Price
$580.00
Role
Director
Holding change
-36.1%
Trade date
Nov 9, 2026
5:42 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.36M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $560.79 to $568.68 a share (average $564.51) in 9 transactions, worth $5.36M in total on Nov 6, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.36M
Shares
9,500
Average price
$564.51
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Nov 6, 2026
4:58 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $1.17M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 1,950 shares of United Therapeutics Corp at $593.14 to $602.49 a share (average $597.75) in 8 transactions, worth $1.17M in total on Nov 5, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$1.17M
Shares
1,950
Average price
$597.75
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Nov 5, 2026
4:55 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.33M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 7,540 shares of United Therapeutics Corp at $562.51 to $591.54 a share (average $573.89) in 24 transactions, worth $4.33M in total on Nov 5, 2026. Shares held after the trade: 326,403 (-0.0%).

Value
$4.33M
Shares
7,540
Average price
$573.89
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Nov 5, 2026
5:22 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $1.05M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 1,723 shares of United Therapeutics Corp at $610.29 to $613.13 a share (average $611.06) in 4 transactions, worth $1.05M in total on Nov 4, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$1.05M
Shares
1,723
Average price
$611.06
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Nov 4, 2026
5:21 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $4.66M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 7,777 shares of United Therapeutics Corp at $580.70 to $609.09 a share (average $599.64) in 24 transactions, worth $4.66M in total on Nov 4, 2026. Shares held after the trade: 326,166 (-0.4%).

Value
$4.66M
Shares
7,777
Average price
$599.64
Role
Chairperson & CEO
Holding change
-0.4%
Trade date
Nov 4, 2026
5:15 PM ET Form 4
Insider Selling

United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.97M of Stock

Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $593.90 to $602.72 a share (average $598.67) in 9 transactions, worth $4.97M in total on Nov 5, 2026. Shares held after the trade: 45,172 (-2.4%).

Value
$4.97M
Shares
8,300
Average price
$598.67
Role
EVP & General Counsel
Holding change
-2.4%
Trade date
Nov 5, 2026
4:39 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.72M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $598.68 to $605.97 a share (average $601.92) in 8 transactions, worth $5.72M in total on Nov 3, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.72M
Shares
9,500
Average price
$601.92
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Nov 3, 2026
6:32 AM ET 8-K
Financial Results

United Therapeutics Financial Results

United Therapeutics reported third quarter 2026 total revenues of $832.5 million, a 4% increase year-over-year, driven primarily by growth in Tyvaso DPI and Orenitram sales. Net income for the quarter was $258.6 million, or $5.71 per diluted share, representing a 24% decrease compared to the prior year period.

Term
Q3 2026

“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve.”

Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics

“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization.”

Michael Benkowitz, President and Chief Operating Officer of United Therapeutics
4:31 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.66M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $593.09 to $598.84 a share (average $596.22) in 7 transactions, worth $5.66M in total on Nov 2, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$5.66M
Shares
9,500
Average price
$596.22
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Nov 2, 2026
4:34 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.7M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $594.92 to $608.05 a share (average $600.09) in 13 transactions, worth $5.7M in total on Oct 30, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.7M
Shares
9,500
Average price
$600.09
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 30, 2026
4:31 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.65M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $590.43 to $599.30 a share (average $594.78) in 9 transactions, worth $5.65M in total on Oct 29, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.65M
Shares
9,500
Average price
$594.78
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 29, 2026
4:30 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.56M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $583.50 to $588.39 a share (average $585.49) in 6 transactions, worth $5.56M in total on Oct 28, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.56M
Shares
9,500
Average price
$585.49
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 28, 2026
4:31 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.58M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $582.66 to $592.84 a share (average $587.73) in 11 transactions, worth $5.58M in total on Oct 27, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.58M
Shares
9,500
Average price
$587.73
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 27, 2026
4:31 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.59M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $585.71 to $592.92 a share (average $588.64) in 8 transactions, worth $5.59M in total on Oct 26, 2026. Shares held after the trade: 324,443 (-0.2%).

Value
$5.59M
Shares
9,500
Average price
$588.64
Role
Chairperson & CEO
Holding change
-0.2%
Trade date
Oct 26, 2026
4:31 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.54M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $577.68 to $588.00 a share (average $582.76) in 11 transactions, worth $5.54M in total on Oct 23, 2026. Shares held after the trade: 324,443 (-0.2%).

Value
$5.54M
Shares
9,500
Average price
$582.76
Role
Chairperson & CEO
Holding change
-0.2%
Trade date
Oct 23, 2026
4:35 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.54M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $562.97 to $590.40 a share (average $583.38) in 21 transactions, worth $5.54M in total on Oct 22, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.54M
Shares
9,500
Average price
$583.38
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 22, 2026
4:36 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.32M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $552.52 to $566.43 a share (average $560.07) in 14 transactions, worth $5.32M in total on Oct 21, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.32M
Shares
9,500
Average price
$560.07
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 21, 2026
7:01 AM ET 8-K
Stock Buyback

United Therapeutics Announces $2B Stock Buyback

United Therapeutics' Board of Directors authorized a new $2.0 billion share repurchase program for its common stock. The authorization is effective for one year through October 21, 2027, and allows for repurchases via open market transactions, accelerated share repurchase programs, or private deals.

Value
$2B
Term
1 year
4:35 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.26M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $546.84 to $563.56 a share (average $553.87) in 17 transactions, worth $5.26M in total on Oct 20, 2026. Shares held after the trade: 324,443 (-0.1%).

Value
$5.26M
Shares
9,500
Average price
$553.87
Role
Chairperson & CEO
Holding change
-0.1%
Trade date
Oct 20, 2026
4:36 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.16M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $534.75 to $556.88 a share (average $543.32) in 19 transactions, worth $5.16M in total on Oct 19, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.16M
Shares
9,500
Average price
$543.32
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 19, 2026
4:34 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.08M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $530.48 to $543.85 a share (average $534.66) in 13 transactions, worth $5.08M in total on Oct 16, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.08M
Shares
9,500
Average price
$534.66
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 16, 2026
4:35 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.19M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $540.48 to $551.50 a share (average $546.65) in 12 transactions, worth $5.19M in total on Oct 15, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.19M
Shares
9,500
Average price
$546.65
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 15, 2026
4:34 PM ET Form 4
Insider Selling

United Therapeutics EVP & General Counsel Paul A. Mahon Sells $4.52M of Stock

Paul A. Mahon, EVP & General Counsel, sold 8,300 shares of United Therapeutics Corp at $541.64 to $546.56 a share (average $544.30) in 6 transactions, worth $4.52M in total on Oct 15, 2026. Shares held after the trade: 45,172 (-1.6%).

Value
$4.52M
Shares
8,300
Average price
$544.30
Role
EVP & General Counsel
Holding change
-1.6%
Trade date
Oct 15, 2026
4:35 PM ET Form 4
Insider Selling

United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells $5.13M of Stock

Martine A. Rothblatt, Chairperson & CEO, sold 9,500 shares of United Therapeutics Corp at $526.07 to $546.00 a share (average $539.99) in 16 transactions, worth $5.13M in total on Oct 14, 2026. Shares held after the trade: 324,443 (-0.0%).

Value
$5.13M
Shares
9,500
Average price
$539.99
Role
Chairperson & CEO
Holding change
-0.0%
Trade date
Oct 14, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.